Gracell gives sneak peek into leukemia CAR-T cell program ahead of EHA
Gracell Biotechnologies said Thursday afternoon that its CAR-T treatment for patients with B cell acute lymphoblastic leukemia, or B-ALL, helped clear signs of cancer in seven of nine patients at a median follow-up of over one year.
In a Phase I trial in China of Gracell’s CAR-T treatment, dubbed GC007g, with patients with relapsed B-ALL, all patients went into remission one month after treatment. At a median follow-up of 445 days (with a wide range of follow-up from 218 to 649 days), seven of nine patients remained in remission, while two had a CD19-negative relapse.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
